CCL19 and neoplasm: Among the 11 APC-binding molecules tested, CCL19 was selected for further characterization due to its ability to induce strong and balanced neoepitope-specific T-cell responses, and render complete tumor rejection in a prophylactic setting and partial tumor control in an early-therapeutic setup.